Fig. 2. PFS in patients receiving bevacizumab maintenance in the first-line setting: median PFS in group 1 (<65 years) 17 months vs. 11 months in group 2 (≥65 years) (p=0.09).
PFS, progression free survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.